论文部分内容阅读
作者选择重症再生障碍性贫血(SAA)不宜作骨髓移植的病人,或非重症再生障碍性贫血(MAA)的病人,其粒细胞<500/μl,血小板<20000/μl,或需长期输注红细胞者加入本研究。将病人随机分为A组[抗淋巴细胞球蛋白(ALG)+甲基强的松龙(MP)]或B组[ALG+MP+环孢菌素A(CsA)]。ALG0.75ml/kg×8天,静滴:MP第1-8天5mg/kg/日,第9 14天1mg/kg/日,第15 29天为递减期;CsA12mg/kg,至少3个月,剂量根据血清学水平调整。MP和CsA为口服给药。结果35例已随访3 18个月(平均11个月)。其中A组15例,B组20例。两组的年龄、病程和病情具有可比性,其中S八A在A组与B组分别占78%和70%。治疗3个月内A组中7例(47%)和B组中
The authors selected patients with severe aplastic anemia (SAA) not suitable for bone marrow transplantation or patients with non-severe aplastic anemia (MAA) with granulocytes <500 / μl, platelets <20,000 / μl, or long-term infusion of erythrocytes Join this study. Patients were randomized to A group [anti-lymphocyte globulin (ALG) + methylprednisolone (MP)] or group B [ALG + MP + cyclosporin A (CsA)]. ALG0.75ml / kg × 8d, intravenous drip: MP on day 1-8 5mg / kg / day, on day 9 14th 1mg / kg / day, on day 15-29 for decreasing; CsA12mg / kg for at least 3 months The dose was adjusted according to the serological level. MP and CsA are administered orally. Results 35 cases were followed up for 3 18 months (mean 11 months). There were 15 cases in group A and 20 cases in group B. The age, course of disease and disease were comparable in both groups, of which SBA was 78% and 70% in group A and B, respectively. Within 3 months of treatment, 7 patients (47%) in group A and group B